Experimental lymphoma drug IPH6501 tested in early trial – but study halted
NCT ID NCT06088654
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested an experimental drug called IPH6501 in 23 people with certain types of Non-Hodgkin lymphoma that had returned or stopped responding to prior treatments. The goal was to check safety and find the right dose, while also looking for signs that the drug shrinks tumors. The study was terminated early, so results are limited and it is unclear if the drug will move forward.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IPH6501 (an experimental drug that targets CD20 on cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for people with certain types of Non-Hodgkin lymphoma that have not responded to other therapies.
What could go wrong
This is a very early (first-in-human) trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Health
Heidelberg, Australia
-
Cedars Sinai
Los Angeles, California, 90048, United States
-
Centre Hospitalier Regional Universitaire de Lille
Lille, France
-
Centre Hospitalier Universitaire de Nantes
Nantes, France
-
City of Hope
Duarte, California, 91010, United States
-
Hospices Civils de Lyon
Lyon, 69002, France
-
Hôpital de la Coception
Marseille, 13005, France
-
Icahn School Of Medicine At Mount Sinai
New York, New York, 10029, United States
-
Institute Bergonie
Bordeaux, France
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Monash Health
Clayton, Victoria, 3168, Australia
-
Peninsula Private Hospital
Frankston, Victoria, 3910, Australia
-
Siteman Cancer Center
St Louis, Missouri, 63110, United States
-
Wollongong Private Hospital
Wollongong, New South Wales, 2500, Australia